Ophthalmology Times

Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...
Fierce Biotech

Ollin eyes phase 3 after bispecific tops Vabysmo in early-stage trial, clearing more retinal disease faster

After unsheathing just a few months ago, Ollin Biosciences’ next-gen bispecific antibody cleared more disease faster than ...
Monthly Prescribing Reference

Vabysmo Approved for Macular Edema Following Retinal Vein Occlusion

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...
Healio

FDA approves Eylea HD for macular edema after retinal vein occlusion

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...
Monthly Prescribing Reference

Faricimab Under Review for Macular Edema Following Retinal Vein Occlusion

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...
The American Journal of Managed Care

Study Confirms Retinal Structural Associations Between Retinitis Pigmentosa, Macular Edema

Researchers also suggest potential new genetic associations with macular edema, which warrant further research. A study published in Scientific Reports confirmed previously identified retinal ...
Healio

FDA approves Vabysmo for macular edema due to retinal vein occlusion

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...